Substitute for form 1449A/PTO				Complete If Known		
				Application Number	Unassigned	
INFO	ORMATION	I DI	SCLOSURE	Filing Date	Herewith	
STA	TEMENT E	3Y <i>A</i>	NPPLICANT	First Named Inventor	Karimisetty, Srikanth	
1				Art Unit	Unassigned	
	(use as many sh	ieets a	s necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	021756-002100US	

	U.S. PATENT DOCUMENTS+						
	Document Number						
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Ö	AA	US-6,456,955 B1	09-24-2002	Andrews et al.			
0.9	AB	US-6,584,459 B1	06-24-2003	Chang et al.			
0.9	AC	US-2002-0023083 A1	02-21-2002	Durkalski			
0-0	AD	US-2002-0107652 A1	08-08-2002	Andrews et al.			
0.0	AE	US-2002-0143726 A1	10-03-2002	Planalp et at.	 -		
0.0	AF	US-2003-0069795 A1	04-10-2003	Boyd et al.			
2.0	AG	US-2003-0069894 A1	04-10-2003	Cotter et al.			
0,0	AH	US-2003-0088776 A1	05-08-2003	Lin et al.			
					•		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document				Name of Patentee or	Pages, Columns, Lines,	
		Country Code ³	Number ⁴	(Gnd Code ⁶ (#Imown)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
					·			
								<u> </u>
								<u> </u>
								<u> </u>
								<u> </u>
	L		··					
								<u> </u>

Examiner	- 0	Date	1 /11/21
	6 V 1 10 10		I 数 /// / 少6
Signature	Eller 10 10	Considered	1 6777.7
			· · · · · · · · · · · · · · · · · · ·

Substitute for form 1449B/PTO	Complete if Kn wn			
INFORMATION DICCLOSURE	Application Number	Unassigned		
INFORMATION DISCLOSURE	Filing Date	Herewith		
STATEMENT BY APPLICANT	First Named Inventor	Karimisetty, Srikanth		
	Art Unit	Unassigned		
. (use as many sheets as necessary)	Examiner Name	Unassigned		
Sheet 2 of 2	Attorney Docket Number	021756-002100US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
6-0	Al	*FDA 21 CFR Part 11,* Document Resources, http://www.documentresources.com/document/21cfrpart11.html, pp. 1-2, printed June 23, 2003.	
0.0	٨	*The Role of Technology Solutions in the Pharmaceutical and Biotechnology Industries' Search for 21 CFR Part 11 Compliance, *Life Science CIO Forum, www.lifesciencesCIOforum.com, pp. 1-7 (2002).	
0-0	AK	*21CFR Part 11 Opportunity or Challenge? With an Analysis of Oracle's OPM, Life Science CIO Forum, www.lifesciencesClOforum.com, pp. 1-14 (2002).	
			1
		·	
-			
-			
$\overline{}$			

Examiner Signature	Alubuso :	Date Considered	3/1/06	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.